GlassScriptPhysician profile
Conchita Paz
NPI 1316982366
$15,799.96
in general payments reported to CMS, 2019-2025
42 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,728 · 2020: $1,871 · 2021: $2,089 · 2022: $2,750 · 2023: $1,576 · 2024: $3,048 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,896 · Consulting Fee: $1,450 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,895.61 |
| Consulting Fee | $1,450.00 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,486.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,144.40 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,367.24 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,171.75 | 2019-2024 | Ofev, Jardiance |
| Abbvie INC. | $985.23 | 2021-2025 | |
| Amgen INC. | $870.94 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $630.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $589.82 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $497.38 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $391.15 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $360.87 | 2019-2022 | |
| Amarin Pharma, INC. | $214.01 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $212.22 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $195.30 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $182.55 | 2020-2025 | Gvoke Hypopen |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conchita Paz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.